PROGRAM MENU
Educational Program

THSNA programming is focused on presenting the most current issues in Hemostasis and Thrombosis. The THSNA 2020 program will include on demand access to recorded talks covering four educational tracks as well as live panel discussion sessions, a nursing workshop, digital posters, corporate symposia, and a virtual exhibit hall with commercial booths.

Note that all timea are listed in Eastern Daylight Time (EDT) and any aspect of this program is subject to change.

  Tue - Oct 27      Wed - Oct 28      Thu - Oct 29      Fri - Oct 30   

THURSDAY, OCTOBER 29

10:00 - 11:30 AM
PLENARY SESSION
PLENARY 3: ENSURING AND PROMOTING BEST CARE
Chair/Organizer: Robert Sidonio, Cathy Hayward

This Plenary will provide unique, expert perspectives on the challenges of ensuring that the best care is provided to persons with thrombosis or bleeding problems. The speakers will touch on broad issues that influence the quality of care, from choices between treatments to advocacy and health promotion.



PROMOTING PATIENT SAFETY
Jesse Roach. Centers for Medicare and Medicaid Services


CHOOSING BETWEEN NEW AND OLD THERAPIES FOR THROMBOSIS
Stephan Moll. Unviersity of North Carolina School of Medicine


ENSURING THE BEST CARE FOR PATIENTS WITH CONGENITAL AND ACQUIRED BLEEDING PROBLEMS. WHAT ARE OUR CHALLENGES
Len Valentino. National Hemophilia Foundation

12:15 - 1:15 PM
SATELLITE SYMPOSIUM
CORPORATE LUNCH SYMPOSIUM: PFIZER MEDICAL SYMPOSIUM: PERSPECTIVES ON HEMOPHILIA B CARE IN AN ERA OF ADVANCED THERAPEUTICS AND EXTRAVASCULAR FIX SCIENCE: PAST, PRESENT AND FUTURE CONSIDERATIONS

Sponsored By: Pfizer

The field of hemophilia has rapidly evolved over the last decade, with a plethora of treatment options currently available, and in clinical development. Historically, the management of hemophilia B has been largely extrapolated from our scientific and clinical understanding of hemophilia A. However, a renewed focus on research in hemophilia B is changing our understanding of the science underpinning this disease and further expanding possibilities for these patients.

In this era of rapidly evolving science and technology, it is important to reflect on current management strategies for people with hemophilia B, to support the preservation of joint function and optimize the potential offered by future approaches to care.

Our satellite symposium will explore mechanisms for advancing the care of people with hemophilia B in this era of advanced therapeutics. Through discussing the role of real-world data, and our expanding understanding of the science of hemophilia B, we will explore how this progress is driving innovation and resetting our expectations of standards of care.

SESSION HANDOUTS
Save the Date Flyer
Symposium Program Booklet



CORPORATE LUNCH SYMPOSIUM: PROVEN BLEED PROTECTION WITH EXTENDED FACTOR IX DOSING: LEARN MORE ABOUT THE EXTENSION STUDIES

Sponsored By: CSL Behring

Join us as we discuss NEW published data from two extension studies, affirming long-lasting efficacy with up to 4 years of evaluating adult and adolescent patients treated prophylactically at both 7- and 14-day extended intervals.


2:00 - 3:30 PM
BASIC SCIENCE
NEW INSIGHTS ON MECHANISMS
Chair/Organizer: Anne Rose, Rodney Camire

Welcome to the Live Session. The live stream will appear below at the scheduled time for all logged-in registrants to view. If you see an Ask a Question option to the right of the presentation, we highly encourage questions during the live events to facilitate scheduled Q&A portions of the session. Please be sure to get your questions in early. Theater Mode offers you the option to view a larger version of the presentation. Once the session concludes, a recording will be available for on-demand access if this session has been approved for enduring content posting.



ADVANCES IN UNDERSTANDING THE COFACTOR FUNCTION OF FACTOR V
Rodney Camire. University of Pennsylvania/Children's Hospital of Philadelphia


UPDATE ON THE INTERPLAY BETWEEN COAGULATION AND COMPLEMENT SYSTEMS
Edward Conway. University of British Columbia Centre for Blood Research


UNDERSTANDING THE CLOT FROM STUDIES OF FIBRIN AND FACTOR XIII
JW Weisel. University of Pennsylvania

2:00 - 3:30 PM
HEMOSTASIS
NEW STRATEGIES IN HEMOPHILIA THERAPY
Chair/Organizer: Michael Recht, Shannon Jackson

Welcome to the Live Session. The live stream will appear below at the scheduled time for all logged-in registrants to view. If you see an Ask a Question option to the right of the presentation, we highly encourage questions during the live events to facilitate scheduled Q&A portions of the session. Please be sure to get your questions in early. Theater Mode offers you the option to view a larger version of the presentation. Once the session concludes, a recording will be available for on-demand access if this session has been approved for enduring content posting.



CHALLENGING BLEEDING EVENTS IN PATIENTS ON NOVEL HEMOPHILIA THERAPIES
Glaivy Batsuli. Emory University a Aflac Cancer and Blood Disorders Center at Children's Healthcare of Atlanta


TOLERANCE IN THE AGE OF NON-FACTOR REPLACEMENT THERAPY
Shannon Meeks. Emory University/Children's Healthcare of Atlanta


HOW NEW THERAPIES ARE IMPACTING HEMOPHILIA TREATMENT CENTERS
Jim Munn. Michigan Medicine

2:00 - 3:30 PM
THROMBOSIS / LABORATORY
STARTING AND STOPPING DOACS
Chair/Organizer: Arthur Allen, Pall Onunderson

Welcome to the Live Session. The live stream will appear below at the scheduled time for all logged-in registrants to view. If you see an Ask a Question option to the right of the presentation, we highly encourage questions during the live events to facilitate scheduled Q&A portions of the session. Please be sure to get your questions in early. Theater Mode offers you the option to view a larger version of the presentation. Once the session concludes, a recording will be available for on-demand access if this session has been approved for enduring content posting.



PLANNED INTERRUPTION OF DOAC THERAPY
James Douketis. McMaster University


EMERGENCY REVERSAL OF DOAC THERAPY: CURRENT EVIDENCE ON BEST APPROACHES
Deb Siegal. McMaster University


LABORATORY SUPPORT FOR PATIENTS ON DOAC THERAPY: CHALLENGES TO CHECKING FOR DRUG AND MEASURING LEVELS
Adam Cuker. University of Pennsylvania

4:15 - 5:45 PM
HEMOSTASIS / LABORATORY
EVALUATING FOR BLEEDING DISORDERS: WHAT TO DO AFTER THE PATIENT WALKS THROUGH YOUR DOOR
Chair/Organizer: Stacy Croteau, Maria Santaella

Welcome to the Live Session. The live stream will appear below at the scheduled time for all logged-in registrants to view. If you see an Ask a Question option to the right of the presentation, we highly encourage questions during the live events to facilitate scheduled Q&A portions of the session. Please be sure to get your questions in early. Theater Mode offers you the option to view a larger version of the presentation. Once the session concludes, a recording will be available for on-demand access if this session has been approved for enduring content posting.



BLEEDING ASSESSMENT: KEY ISSUES FOR PATIENT EVALUATION FOR CLINICAL PRACTICE AND RESEARCH ACROSS THE AGE SPECTRUM.
Sarah O'Brien.


OVERVIEW ON THE LABORATORY ASSESSMENT OF PATIENTS REFERRED FOR BLEEDING PROBLEMS.
Cathy Hayward. McMaster University, Hamilton Regional Laboratory Medicine Program


NURSING PERSPECTIVES ON THE NEEDS OF PATIENTS WITH BLEEDING PROBLEMS, WITH CONSIDERATION OF THEIR QUALITY OF LIFE.
Christine Guelcher. Children's National Hospital

4:15 - 5:45 PM
BASIC SCIENCE
NEW INSIGHTS ON PLATELETS AND THEIR FUNCTIONS
Chair/Organizer: A. Koneti Rao, Jorge DiPaola

Welcome to the Live Session. The live stream will appear below at the scheduled time for all logged-in registrants to view. If you see an Ask a Question option to the right of the presentation, we highly encourage questions during the live events to facilitate scheduled Q&A portions of the session. Please be sure to get your questions in early. Theater Mode offers you the option to view a larger version of the presentation. Once the session concludes, a recording will be available for on-demand access if this session has been approved for enduring content posting.



PLATELET THIOL ISOMERASES: BENCH TO BEDSIDE
Robert Flaumerhaft.


PLATELET-LEUKOCYTE INTERACTIONS MEDIATE STROKE OUTCOMES
Matthew Rondina.


DETERMINANTS OF PLATELET HYPERREACTIVITY WITH AGING
Jorge DiPaola.

4:15 - 5:45 PM
THROMBOSIS
RISK AND BENEFITS OF COMBINATION ANTITHROMBOTIC THERAPY IN CAD: WHEN LESS IS MORE
Chair/Organizer: Eric Grabowski

Welcome to the Live Session. The live stream will appear below at the scheduled time for all logged-in registrants to view. If you see an Ask a Question option to the right of the presentation, we highly encourage questions during the live events to facilitate scheduled Q&A portions of the session. Please be sure to get your questions in early. Theater Mode offers you the option to view a larger version of the presentation. Once the session concludes, a recording will be available for on-demand access if this session has been approved for enduring content posting.



UPDATE ON RESPONSIVENESS TO ANTIPLATELET THERAPY
J. Eduardo Bahena-Lopez. Affiliation: National Institute of Cardiology of Mexico


IS THERE ANY ROLE FOR ASPIRIN IN THE TREATMENT OR PREVENTION OF VENOUS THROMBOSIS?
David Garcia. University of Washington


STABLE CAD AND PERIPHERAL ARTERIAL DISEASE: WHEN SHOULD AN ANTICOAGULANT BE CONSIDERED FOR ADDED PROTECTION
Renato Lopes. Duke Clinical Research Institute

6:00 - 7:00 PM
SATELLITE SYMPOSIUM
ON-DEMAND SYMPOSIUM: A BREAKTHROUGH IN ATTP TREATMENT: NOW RECOMMENDED BY THE ISTH GUIDELINES

Sponsored By: Sanofi Genzyme

The program will provide an overview of acquired thrombotic thrombocytopenic purpura (aTTP) a rare, life-threatening, auto-immune disease - and the urgency for rapid diagnosis and treatment. The program will then review the recently published ISTH Guidelines on the diagnosis and treatment of aTTP with a focus on the first and only FDA-approved therapy indicated for adults with aTTP.

View full prescribing information for an aTTP product here.

MAT-US-2019445-v1. 0-09/2020

Click here to submit a question.



ON-DEMAND SYMPOSIUM: HEMOPHILIA A WITHOUT INHIBITORS: PERSONALIZING THERAPY WITH FACTOR VIII PROPHYLAXIS

Sponsored By: Takeda Pharmaceuticals U. S. A, Inc.

Clinicians and patients face challenges in current factor VIII replacement therapy, including the frequency of intravenous factor infusions as well as patient adherence. Lack of adherence to prophylactic treatment leads to increased frequency of bleeds and development of hemophilic arthropathy. New treatment options for patients with hemophilia A offer the potential for more effective and convenient treatments, including new and emerging prolonged half-life clotting factors such as FVIII-Fc and pegylated FVIII, that offer a therapeutic option with decreased bleeding rates and less frequent infusions. In this case-based, one-hour pre-recorded virtual symposium, renowned hemophilia experts Michael Callaghan, MD, Miguel Escobar, MD, and Guy Young, MD, provide their perspectives on recent changes in Factor VIII replacement therapy management that are improving patient care.

Click here to submit a question about the symposium.

Continuing Education Information: In accordance with ACCME, ANCC, and ACPE requirements, activities are certified for credit through CCO. This program will be certified by CCO for AMA PRA Category 1 Credit, ACPE contact hours, and ANCC contact hours.
Please click on the following link to obtain CME. https://www. clinicaloptions. com/event/HemophiliaChicago2020Eval

Questions? Email customersupport@clinicaloptions. com



ON-DEMAND SYMPOSIUM: MORE THAN ABRS (ANNUAL BLEED RATES): HCP AND PATIENT PERSPECTIVES IN AN EVOLVING HEMOPHILIA TREATMENT LANDSCAPE

Sponsored By: Sanofi Genzyme, Intended for US Healthcare Professionals Only

The use of factor replacement therapy in the treatment of hemophilia has come a long way and continues to change. Join us for a discussion looking beyond ABRs and at how this evolution impacts how we think about treatment approaches for different patients. Topics will include HCP and patient perspectives on how clinical data translate into real world, innovative approaches to patient engagement, with an emphasis on bleed and joint bleed protection. Please see important safety information throughout this presentation and full prescribing information at the links provided below.

Full Prescribing Information for a Hemophilia A treatment
Full Prescribing Information for a Hemophilia B treatment

MAT-US-2021089 v1. 0 10/2020

Click here to submit a question.


6:15 - 7:00 PM
EVENT/OTHER
THSNA NETWORKING HAPPY HOUR: THE CHANGING FACE OF ANTICOAGULATION SERVICES.
Chair/Organizer: Arthur Allen

Open forum to discuss changes AC service staff members are facing with the decline in warfarin utilization and increased use of DOACs. Focus on role as expert consultants, DOAC oversight, and anticoagulation stewardship.


7:00 - 8:00 PM
SHORT TALKS
BLEEDING DISORDER IMPACT


CHARACTERISTICS, COMPLICATIONS, AND SITES OF BLEEDING AMONG INFANTS AND TODDLERS LESS THAN 2 YEARS OF AGE WITH VWD: A REPORT FROM THE UNIVERSAL DATA COLLECTION SURVEILLANCE PROJECT.
Brandi Dupervil 1, Karon Abe1, Sarah O'Brien2, Meredith Oakley1, Roshni Kulkarni3, Vanessa Byams1, Mike Soucie1. 1Division of Blood Disorders, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, GA, USA. 2The Research Institute a Nationwide Children, Columbus, OH, USA. 3Centers for Bleeding and Clotting Disorders, Department of Pediatrics and Human Development, Michigan State University, East Lansing, MI, USA


HEAVY MENSTRUAL BLEEDING IMPACT ON MENTAL HEALTH IN ADOLESCENT AND YOUNG ADULT WOMEN WITH BLEEDING DISORDERS
Mary McGrath1, Elisabeth Quint2, Angela Weyand1. 1Department of Pediatrics, University of Michigan, Ann Arbor, MI, USA. 2Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor, MI, USA


LONG-TERM IMMUNOGENICITY, EFFICACY AND TOLERABILITY OF SIMOCTOCOG ALFA IN PATIENTS WITH SEVERE HAEMOPHILIA A WHO HAD COMPLETED THE NUPROTECT STUDY
Ellis J Neufeld1, Ri J Liesner2, on behalf of the GENA-15 Study Group1. 1St. Jude Children, Memphis, TN, USA. 2Haemophilia Comprehensive Care Centre, Great Ormond Street Hospital for Children, NHS Foundation Trust, London, United Kingdom


SOCIALLY VULNERABLE YOUTH WITH BLEEDING DISORDERS: PILOTING NOVEL INTERVENTIONS IN CHILDREN'S HEALTHCARE (NICH)
David V Wagner, Michael Recht, Susan Lattimore, Kristina Haley, Erin Stang, Kim Spiro, Michael A Harris. Oregon Health and Science University, Portland, OR, USA


BLEEDING DISORDER THERAPY AND OUTCOMES


INCREASED HEMOPHILIA-RELATED DISTRESS IS ASSOCIATED WITH REDUCED ADHERENCE TO FACTOR REPLACEMENT THERAPY.
Sara A. Guasch1, Janet Figueroa 1, Vaughn Barry1, Shanna Mattis1, Tyler W. Buckner2, Duc Q. Tran1, Stephanie Whitten 1, Christine L. Kempton 1. 1Emory University, Atlanta, GA, USA. 2University of Colorado, Aurora, CO, USA


PATIENTS WITH G-HSD/HEDS EVALUATED AT HTCS HAVE SIMILAR CO-MORBIDITES TO THOSE IN THE GENERAL POPULATION
Rohith Jesudas1, Christopher Eberlin2, Sweta Gupta3, Amit Soni4, Diane Neugent4, Nina Hwang4, Vanessa Salinas4, Nicole Crook4, Ateefa Chaudhury4, Christina Laukaitis5. 1Bleeding and clotting disorders institute, Peoria, IL, USA. 2University of Illinois College of Medicine in Peoria, Peoria, IL, USA. 3Indiana Hemophilia and Thrombosis Center, Indianapolis, IN, USA. 4Center for Inherited Blood Disorders, Orange, CA, USA. 5University of Arizona, Tucson, AZ, USA


HEMATOLOGY PROVIDER ATTITUDES AND PRACTICES REGARDING IUD INSERTION IN ADOLESCENTS WITH HEAVY MENSTRUAL BLEEDING WITH AND WITHOUT BLEEDING DISORDERS
Allison Wheeler1, Katherine O'Flynn O'Brien2, Claudia Borzutzky3, Peter Kouides4, Oluyemisi Adeyemi-Fowode2. 1Vanderbilt University Medical Center, Nashville, TN, USA. 2Texas Children's Hospital, Houston, TX, USA. 3Children's Hospital of Los Angeles, Los Angeles, CA, USA. 4Mary M Gooley Hemophilia Treatment Center, Rochester, NY, USA


INHERITED AND ACQUIRED BLEEDING DISORDERS


SECOND-LINE THERAPY WITH FOSTAMATINIB IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA (ITP)
Ralph Boccia1, Waleed Ghanima2, Quentin Hill3, Michelle Sholzberg4, Michael D Tarantino5, Darla Liles6, Yuliya Kreychman7, Robert P Numerof7, Sonia Souza7, Leslie Todd7, Sandra Tong7, James B Bussel8. 1Center for Cancer and Blood Disorders, Bethesda, MD, USA. 2Department of Research, Ostfold Hospital Trust, Sarpsborg and Department of Hematology, Institute of Clinical Medicine, Sarpsborg, Norway. 3Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom. 4Li Ka Shing Knowledge Institute, St. Michael, Toronto, ON, Canada. 5The Bleeding and Clotting Disorders Institute, University of Illinois College of Medicine-Peoria, Peoria, IL, USA. 6East Carolina University Brody School of Medicine, Greenville, NC, USA. 7Rigel Pharmaceuticals, Inc, South San Francisco, CA, USA. 8New York Presbyterian Hosp. Weill Cornell Medical Center, New York, NY, USA


SCREENING FOR FACTOR IX PADUA (R338L) IN PEDIATRIC THROMBOSIS PATIENTS
Benjamin J Samelson-Jones1, 2, 3, James F. Jarrett III1, Leslie J. Raffini1, 2, Valder R. Arruda1, 2, 3. 1The Children's Hospital of Philadelphia, Philadelphia, PA, USA. 2Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 3Raymond G. Perelman Center for Cellular and Molecular Therapeutics, Philadelphia, PA, USA


ASSESSMENT OF RARE BLEEDING DISORDERS IN ADOLESCENT FEMALES WITH UNEXPLAINED BLEEDING
Ruchika Sharma1, 2, Seema Menon2, Michelle Dobratz1, Bridgit Hansen1, Victoria Johnson1, Veronica Flood1, 2. 1Versiti Blood Center of Wisconsin, Milwaukee, WI, USA. 2Medical College of Wisconsin, Milwaukee, WI, USA


THROMBOSIS: CLINICAL


DEVELOPMENT OF A BRIEF SCREENING TOOL FOR EMOTIONAL HARM ASSOCIATED WITH VENOUS THROMBOEMBOLISM
Keith S. Keddington1, Aubrey E. Jones1, Michael Feehan2, Daniel M. Witt1. 1University of Utah College of Pharmacy, Department of Pharmacotherapy, Salt Lake City, UT, USA. 2Kantar LLC, Boston, MA, USA


VENOUS THROMBOEMBOLISM IN PATIENTS WITH UTERINE FIBROIDS
Hira Latif1, Valentina Baez Sosa1, Stephen J. Fernandez2, Nicholas D. Hazen1, James K. Robinson1, Vadim Morozov1, Kelly W. Fitzpatrick1. 1MedStar Washington Hospital Center, Washington, DC, USA. 2MedStar Health Research Institute, Washington, DC, USA


RACIAL DISPARITIES ACROSS AGE GROUPS IN ILLINOIS HOSPITAL ADMISSIONS FOR PULMONARY EMBOLISM
Karlyn Martin1, Megan McCabe2, Joseph Feinglass3, Sadiya Khan2. 1Division of Hematology/Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. 2Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. 3Division of General Internal Medicine and Geriatrics, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA


CHOICE OF ANTICOAGULATION THERAPY AND PERSISTENCE AMONG PATIENTS WITH ATRIAL FIBRILLATION FOLLOWING A SHARED DECISION-MAKING ENCOUNTER
Jeff Nagge1, Sherilyn Houle1, Eunice Chan1, Kristen Stypa1, Ai-Leng Foong1, Ryan McKee2. 1University of Waterloo, Kitchener, ON, Canada. 2Centre for Family Medicine, Kitchener, ON, Canada

7:00 - 7:45 PM
POSTER SESSION
VIRTUAL POSTERS - INFORMATIONAL ONLY

Welcome to this Virtual Poster Session. You may view any poster by clicking on a presentation below. Note that you may also submit questions directly to the author of any presentation using the Ask a Question option. Note that all questions may not receive a response.



A9. INFORMATIONAL ABSTRACT (POSTER ONLY)


1

PATIENT SATISFACTION WITH HEMOPHILIA TREATMENT CENTERS: DIFFERENCES BETWEEN MILDS AND SEVERES FROM THE 2ND NATIONAL US HTC PATIENT SATISFACTION SURVEY
Judith Baker1, 2, Rick Shearer3, Merilee Ashton3, Susan Lattimore4. 1Center for Inherited Blood Disorders, Orange, CA, USA. 2UCLA, Los Angeles, CA, USA. 3University of Colorado, Aurora, CO, USA. 4Oregon Health a Science University, Portlant, OR, USA


2

A ROLE FOR NURSES: HOSPITAL-WIDE ROLL OUT OF EXTREMITY PRECAUTIONS FOR NEW FINDING OF EXTREMITY THROMBOSIS PROCEDURE AT A PEDIATRIC TERTIARY CARE SETTING - A QUALITY IMPROVEMENT INITIATIVE
Marilyn Blumenstein, Emily Roberto. The Children's Hospital of Philadelphia, Philadelphia, PA, USA


3

DEMOGRAPHIC DISTRIBUTION, CLINICAL PHYSIOGNOMICS AND THERAPEUTIC TRIALS OF COVID-19 IN PAKISTANI POPULATION
Asma Naseer Cheema1, 2, Aneeqa Hayat1, Muhammad Younas2, Azra 3, Rubya Khanum4. 1Department of Pathology, Children's Hospital a The Institute of Child Health, Multan Pakistan. 2Department of Pathology, CMH Multan, National University of Medical Sciences, Rawalpindi Pakistan. 3Department of Microbiology, Khyber Medical University, Peshawar Pakistan. 4Department of Pathology, University Medical a Dental College, The University of Faisalabad, Faisalabad Pakistan


5

U. S. EMERGENCY DEPARTMENT VISITS FOR ORAL ANTICOAGULANT-RELATED BLEEDING, 2018
Andrew I. Geller1, Maribeth C. Lovegrove1, Daniel S. Budnitz1, Nadine Shehab2. 1Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, GA, USA. 2Lantana Consulting Group, contractor to the Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, GA, USA


6

PRELIMINARY VALIDATION OF A QUANTITATIVE HUMAN D-DIMER TEST ON A NOVEL HAND HELD LAB-ON-A-CHIP PLATFORM
Nahla M Heikal1, Melissa Stuart1, Wei Wang2, Shanghsuan Lin2, Xiyn Chen2, Robert McBane1, 3. 1Mayo Clinic. Laboratory Medicine and Pathology, Rochester, MN, USA. 2Zepto life technology, St. Paul, MN, USA. 3Mayo Clinic. Department of Medicine, Rochester, MN, USA


7

UTILIZATION OF EMICIZUMAB AS TREATMENT IN ACQUIRED FACTOR VIII DEFICIENCY
Kevin J. Hess, Preysi Patel, Amogh M. Joshi, Adam J. Kotkiewicz. Lehigh Valley Health Network, Allentown, PA, USA


8

ENGAGING PATIENTS AND FAMILIES AT EMICIZUMAB INITIATION
Madolyn Hofstetter, Kelsey Smith, Susan U Lattimore. Oregon Health a Science University, Portland, OR, USA


11

THE CONTRIBUTION OF CELL POPULATION DATA (CPD) COMPARED TO THE CONCENTRATION OF C-REACTIVE PROTEIN IN HOSPITALIZED PATIENTS IN SURGICAL RESUSCITATION IN UNIVERSITY HOSPITAL IBN ROCHD OF CASABLANCA-MOROCCO
Anass JARMOUMI1, Salma HASNANE1, Hanaa BENCHAREF1, Houcine BARROU2, Bouchra OUKKACHE1. 1Hematology laboratory of University Hospital Ibn Rochd, Casablanca, Morocco. 2Surgical resuscitation in University Hospital Ibn Rochd, Casablanca, Morocco


12

HEMOSTATIC EFFICACY OF ACTIVATED PROTHROMBIN COMPLEX CONCENTRATE FOR REVERSAL OF APIXABAN AND RIVAROXABAN INTRACRANIAL HEMORRHAGE
John M. Koerber1, 3, Janet L. Hoffman1, 3, Sean Mertz2, Karissa Fritsch1, Nour Baalbaki3, Anant Krishnan1, Maureen A. Smythe1, 3. 1Beaumont Heatlh, Royal Oak, MI, USA. 2Cleveland Clinic, Cleveland, OH, USA. 3Wayne State University, Detroit, MI, USA


13

HEMIN USE IN PATIENTS WITH ACUTE HEPATIC PORPHYRIA TREATED WITH GIVOSIRAN: A POST HOC ANALYSIS OF THE PHASE 3 ENVISION STUDY
David Kuter 1, Sioban B. Keel 2, Laurent Gouya3, Herbert L. Bonkovsky4, Penelope E. Stein5, David C. Rees5, Samuel M. Silver 6, Charles Parker 7, Manish Thapar8, Zoe Hua9, Amy Simon 9, John J. Ko9, Petro Petrides10. 1Massachusetts General Hospital, Boston, MA, USA. 2University of Washington, Seattle, WA, USA. 3Centre Francais des Porphyries, Paris, France. 4Wake Forest University NC Baptist Health, Winston-Salem, NC, USA. 5King, London, United Kingdom. 6University of Michigan, Ann Arbor, MI, USA. 7University of Utah, Salt Lake City, UT, USA. 8Thomas Jefferson University, Philadelphia, PA, USA. 9Alnylam Pharmaceuticals, Cambridge, MA, USA. 10Hematology Oncology Center Munich, Munich, Germany


14

PHARMACOKINETICS OF RECOMBINANT VON WILLEBRAND FACTOR IN PERIPARTUM MANAGEMENT OF AN ADOLESCENT WITH TYPE 2M VON WILLEBRAND DISEASE
Caitlin Montcrieff1, 2. 1Rhode Island Hemostasis a Thrombosis Center, Providence, RI, USA. 2Hasbro Children's Hospital, Providence, RI, USA


15

PROGNOSTIC CATEGORISATION OF AML PATIENTS BASED ON CD7 AND CD56 EXPRESSION-A TERTIARY CARE CENTER STUDY IN NORTHERN INDIA
Sandeep Rai1, Prof Ritu Gupta2, Saroj Singh3. 1Lab Oncology, AIIMS, New Delhi, India. 2Lab Oncology, AIIMS, New Delhi, India. 3Lab Oncology, AIIMS, New Delhi, India


16

A MACHINE LEARNING APPROACH TO PREDICT DEEP VENOUS THROMBOSIS AMONG HOSPITALIZED PATIENTS
Logan Ryan, Anna Lynn-Palevsky, Samson Mataraso, Emily Pellegrini, Gina Barnes, Abigail Green-Saxena, Jana Hoffman, Jacob Calvert, Ritankar Das. Dascena, Inc, San Francisco, CA, USA


17

COVID-19 CONCERNS IN THE UNITED STATES (US) BLEEDING DISORDERS COMMUNITY
Maria E Santaella, RN-BC, MSN, CPHON, Cynthia Nichols, PhD, Michelle Witkop, DNP, FNP-BC. National Hemophilia Foundation, New York, NY, USA


18

CHARACTERISTICS EVALUATED FOR POTENTIAL ASSOCIATION WITH THROMBOVASCULAR EVENT RISK IN PATIENTS WITH PREVALENT AUTOIMMUNE CONDITIONS: FINDINGS FROM A RAPID EVIDENCE REVIEW
Nila Sathe1, Chris Rabbat2, Juliana Setyawan2. 1Premier, Inc, Charlotte, NC, USA. 2Arena Pharmaceuticals, San Diego, CA, USA


19

CLINICAL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF WILATE DURING PROPHYLAXIS IN PREVIOUSLY TREATED PATIENTS WITH VON WILLEBRAND DISEASE (VWD)
Bruce A Schwartz1, Robert Sidonio2. 1Octapharma, Hoboken, NJ, USA. 22Hemophilia of Georgia Center for Bleeding a Clotting Disorders, Atlanta, GA, USA


20

RISK OF THROMBOVASCULAR EVENTS IS INCREASED IN INDIVIDUALS WITH PREVALENT AUTOIMMUNE DISEASES: FINDINGS FROM A RAPID EVIDENCE REVIEW
Juliana Setyawan1, Nila Sathe2, Chris Rabbat1. 1Arena Pharmaceuticals, San Diego, CA, USA. 2Premier, Inc, Charlotte, NC, USA


21

DISEASE BURDEN AND HEALTHCARE UTILIZATION AMONG PATIENTS WITH ACUTE INTERMITTENT PORPHYRIA EXPERIENCING CHRONIC PAIN: ANALYSES FROM A NATIONAL HEALTHCARE DATABASE
Samuel M. Silver 1, Angelika L. Erwin 2, Stephen Meninger3, Joseph Tkacz4, Virgina Noxon4, John J. Ko3. 1University of Michigan Medical Center, Ann Arbor, MI, USA. 2Cleveland Clinic, Cleveland, OH, USA. 3Alnylam Pharmaceuticals, Cambridge, MA, USA. 4IBM Watson Health, Bethesda, MD, USA


22

TWELVE-MONTH INTERIM ANALYSIS OF EFFICACY AND SAFETY OF GIVOSIRAN, AN RNAI THERAPEUTIC FOR AHP, IN THE ENVISION OPEN LABEL EXTENSION
John P. Smith. University of Utah, Salt Lake City, UT, USA


23

RETROSPECTIVE ANALYSIS OF TEN YEARS OF PT AND APTT VALIDATION DATA IN A REFERENCE LAB
Dan A Stephens, Ronda A Crist, George M Rogers, Kristi J Smock, Karen Moser. ARUP Institute for Clinical and Experimental Pathologyr, Salt Lake City, UT, USA


24

SUCCESSFUL USE OF TISSUE PLASMINOGEN ACTIVATOR IN INFANTS WITH LIFE THREATENING THROMBOSIS ON EXTRACORPOREAL MEMBRANE OXYGENATION LIFE SUPPORT - A CASE REPORT
Dena R Wideman1 , Kristina A D'Agostino1. 2. 1Children's Mercy, Kansas City, MO, USA. 2University of Missouri Kansas City, Kansas City, MO, USA


25

ANTIBODY RESPONSE AGAINST COVID-19 AMONG HEALTHCARE WORKERS
Muhammad Younas1, Kamran Afzal1, Asma Khan1, Hamid Iqbal1, Kainat Younas3, Asma Naseer Cheema1, 2. 1CMH Multan, National University of Medical Sciences, Multan Pakistan. 2Children's Hospital a The Institute of Child Health, Multan Pakistan. 3Rawalpindi Medical University, Rawalpindi Pakistan


VIRTUAL POSTERS - PATHOPHYSIOLOGY OF THROMBOSIS

Welcome to this Virtual Poster Session. You may view any poster by clicking on a presentation below. Note that you may also submit questions directly to the author of any presentation using the Ask a Question option. Note that all questions may not receive a response.



A2. PLATELET ACTIVATION AND BIOCHEMISTRY


6

EVIDENCE OF THE P75 PAN-NEUROTROPHIC RECEPTOR IN PLATELETS AND COMPARISON TO THE ISOFORM FOUND IN THE BRAIN
Samuel Fleury1, 2, Imane Boukhatem1, 2, Jessica Le Blanc1, 2, Melanie Welman1, Marie Lordkipanidze1, 2. 1Montreal Heart Institute, Montreal, QC, Canada. 2Faculty of Pharmacy, Universite de Montreal, Montreal, QC, Canada


11

ENHANCING TRANSFUSABLE PLATELETS USING MRNA THERAPY TO PRODUCE EXOGENOUS PROTEINS
Jerry Leung, Andrew Hagner, Dominik Witzigmann, Peter Zandstra, Pieter Cullis, Christian Kastrup. University of British Columbia, Vancouver, BC, Canada


23

UTILIZATION OF THROMBOELASTOGRAPHY WITH PLATELET MAPPING TO GUIDE PERIOPERATIVE MANAGEMENT OF INTRAVENOUS IMMUNOGLOBULIN, STEROIDS, AND BLOOD COMPONENT THERAPY IN A PATIENT WITH IDIOPATHIC THROMBOCYTOPENIA PURPURA REQUIRING EMERGENCY CORONARY ARTERY BYPASS GRAFTING.
Mark Walsh, MD1, Jordan Hatch, BS2, Hau C Kwaan, MD3, Faran Bokhari, MD, FACS4, Scott Thomas, MD5, Gina Arsenault, MT (ASCP), MSA5, Gerald Rinon, MT (ASCP)5, Robert March, MD1, Christopher Trumpower, CCP1, Rolan Pascual, MD6, Ashfaq Turk, MD1, Shareen Lee, MS1. 1St. Joseph Regional Medical Center, Mishawaka, IN, USA. 2Indiana University School of Medicine, South Bend, IN, USA. 3Division of Hematology-Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA. 4John H. Stroger, Jr. Hospital, Chicago, IL, USA. 5Beacon Health Systems, South Bend, IN, USA. 6Michiana Hematology and Oncology, Mishawaka, IN, USA


24

APOLIPOPROTEIN A-IV IS AN ENDOGENOUS INHIBITOR OF THROMBOSIS: THE ROLES OF POLYMORPHISMS IN THE RISK OF CARDIOVASCULAR DISEASE
Si-Yang Yu1, 5, Daniel MacKeigan1, 2, 4, Miguel Neves1, 6, 7, Pingguo Chen1, 6, 7, Heyu Ni1-4, 6, 7. 1Department of Laboratory Medicine, Keenan Research Centre for Biomedical Science, Li Ka Shing Knowledge Institute, St. Michael, Toronto, ON, Canada. 2Department of Physiology, University of Toronto, Toronto, ON, Canada. 3Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada. 4Faculty of Medicine, University of Toronto, Toronto, ON, Canada. 5Department of Cardiovascular Medicine, The Second Xiangya Hospital of Central South University, Changsha, China. 6Canadian Blood Services Centre for Innovation, Toronto, ON, Canada. 7Toronto Platelet Immunobiology Group, Toronto, ON, Canada


A3. VASCULAR WALL BIOLOGY, ENDOTHELIAL PROGENITOR CELLS AND PLATELET ADHESION


9

COLLAGEN TURNOVER MARKERS IN HEMOPHILIA
Hira Latif1, Syed W Haider1, Craig M Kessler2. 1MedStar Washington Hospital Center, Washington, DC, USA. 2MedStar Georgetown University Hospital, Washington, DC, USA


A4. DISORDERS OF PLATELET NUMBER OR FUNCTION


1

IMPACT OF FIRST LINE CORTICOSTEROID CHOICE ON PATIENT OUTCOMES IN ACUTE IMMUNE THROMBOCYTOPENIA
Sowda Ahmed, Maureen Laschen, Surbhi Shah. University of Minnesota Medical School, Minneapolis, MN, USA


3

REACTIVE THROMBOCYTOSIS IN PEDIATRIC POPULATION: ANALYSIS OF INDOOR PATIENTS IN A TERTIARY CARE HOSPITAL
Asma N Cheema1, Zulfiqar A Rana2, Zille Rubab1. 1Department of Pathology, Children's Hospital a The Institute of Child Health, Multan, Pakistan. 2Department of Hematology a Oncology, Children's Hospital a The Institute of Child Health, Multan, Pakistan


4

SUCCESSFUL PERIPARTUM MANAGEMENT IN BERNARD SOULIER SYNDROME WITH SEVERE THROMBOCYTOPENIA AND A PREVIOUSLY UNREPORTED GP1BA PATHOLOGIC VARIANT.
Colleen Ciccosanti1, Claire Philipp2. 1Rutgers Robert Wood Johnson Medical School, Department of Medicine, New Brunswick, NJ, USA. 2Rutgers Robert Wood Johnson Medical School, Department of Hematology, New Brunswick, NJ, USA


5

HEPATIC DISORDERS CONTRIBUTE TO PLATELET DYSFUNCTION
Ambar Farooqui, Cassandra Bacher, Fakiha Siddiqui, Bharathi Darvath, Debra Hoppensteadt, Omer Iqbal, Jawed Fareed, Magdalena George, David VanThiel. Loyola University Medical Center, Maywood, IL, USA


10

EVALUATION OF ANTICOAGULATION PRESCRIBING PATTERNS IN PATIENTS WITH SUSPECTED OR CONFIRMED HEPARIN-INDUCED THROMBOCYTOPENIA
Jona Lekura, Ashley Semma, Mya Tran, Ahlam Almansoub, Klarita Seitllari, Philip Kuriakose. Henry Ford Health System, Detroit, MI, USA


12

ANALYSIS OF HEPARIN-INDUCED THROMBOCYTOPENIA (HIT) TESTING AND IMPLEMENTATION OF ELECTRONIC RECORD BASED CALCULATION OF 4T SCORE
Hannah L McRae1, Rialnat Lawal2, Mofiyin Obadina2, Frank Akwaa3, Majed Refaai1, 3. 1Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY, USA. 2Department of Medicine, University of Rochester Medical Center, Rochester, NY, USA. 3Department of Medicine, Division of Hematology/Oncology, Rochester, NY, USA


13

EVALUATION OF LIGHT TRANSMISSION AGGREGOMETRY ON THE ROUTINE COAGULATION ANALYZER SYSMEX CS-2500
Safaa Mghinia1, 2, Yamna lanouari1, 2, mohamed nady1, karima mikou3, Bouchra Oukkache1, 2. 1Hematology Laboratory, CHU Ibn Rochd, Casablanca, Morocco. 2Hassan II University of Casablanca, Faculty of Medicine and Pharmacy, Casablanca, Morocco. 3Scientific Department, Megaflex sarl, Casablanca, Morocco


16

CLINICAL APPLICATION OF THE 4TS SCORE AND PLATELET COUNT TRENDS IN PATIENTS ON EXTRACORPOREAL MEMBRANE OXYGENATION WITH HEPARIN-INDUCED THROMBOCYTOPENIA - A SINGLE INSTITUTION STUDY
Anil K. Rengan1, Daniel Stapor1, Mark Weiner1, Hauqing Zhao1, Nadia Ali2. 1Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA. 2Department of Hematology at Temple University Hospital, Philadelphia, PA, USA


17

COMPARISON OF TWO DIFFERENT ELISA METHODS FOR HEPARIN-INDUCED THROMBOCYTOPENIA (HIT) SCREENING ON AN AUTOMATED ELISA PLATFORM
Paul W Riley, John G Chromczak. Diagnostica Stago, Inc, Parsippany, NJ, USA


18

WHOLE BLOOD IMPENDENCE AGGREGOMETRY AS A SCREEN FOR PLATELET DENSE GRANULE DEFICIENCY
Marian A. Rollins-Raval, Jay S. Raval, Richard A. Marlar. University of New Mexico, Albuquerque, NM, USA


19

PLATELET REFRACTORINESS AND THE ROLE OF LEUCODEPLETION BEFORE BONE MARROW TRANSPLANTATION IN SICKLE CELL DISEASE PATIENTS
Ambreen Sheikh. Dow University, Karachi Pakistan


20

GAUCHER DISEASE SCREENING IN PATIENTS WITH THROMBOCYTOPENIA: A CROSS-SECTIONAL STUDY
Vidushi Swarup1, Nicole Veloce1, Aziz Jiwajee1, Hina R Hanif1, 4, Pauline Manuel1, Gloria Lim1-3, Rosane Nisenbaum5, Cyrus Hsia6, Michelle Sholzberg1-5. 1Hematology-Oncology Clinical Research Group, St. Michael's Hospital, Toronto, ON, Canada. 2Division of Hematology, Department of Medicine, St. Michael's Hospital, Toronto, ON, Canada. 3Department of Medicine, University of Toronto, Toronto, ON, Canada. 4Department of Laboratory Medicine and Pathobiology, St. Michael's Hospital, Toronto, ON, Canada. 5Applied Health Research Centre, MAP Centre for Urban Health Solutions, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, ON, Canada. 6Division of Hematology, Department of Medicine, London Health Sciences Centre, Toronto, ON, Canada


22

LASER SPECKLE AGGREGOMETRY: A NOVEL TECHNIQUE FOR MONITORING PLATELETS FUNCTION
Diane M. Tshikudi1, 2, Asael Papour1, 2, Xin Liang1, 2, John Barranco1, Michael N. Andrawes1, Seemantini K. Nadkarni1, 2, 3. 1Wellman Center for Photomedicine, Boston, MA, USA. 2Massachusetts General Hospital, Boston, MA, USA. 3Harvard Medical School, Boston, MA, USA


A7. PATHOPHYSIOLOGY OF THROMBOSIS


2

UPREGULATION OF C-REACTIVE PROTEIN, PLASMINOGEN ACTIVATOR INHIBITOR-1, MMP-9, FIBRONECTIN, AND OSTEOPONTIN FOLLOWING TOTAL KNEE REPLACEMENT AND HIP REPLACEMENT SURGERY (TKA AND THA).
Maryanne Amour, Fakiha Siddiqui, Debra Hoppensteadt, Meriam Ben Hadj Tahar, Jawed Fareed. Loyola University Medical Center, Maywood, IL, USA


7

PHYSICAL ACTIVITY IN CHILDREN AT RISK OF POST-THROMBOTIC SYNDROME (PACT): A PILOT RANDOMIZED CONTROLLED TRIAL
Rida Hasan 1 , Maria Hanna1, Kendra Malone2, Song Zhang1, Ravi Sarode 1, Janna Journeycake3, Ayesha Zia1. 1University of Texas Southwestern Medical Center, Dallas, TX, USA. 2Children's Medical Center, Dallas, TX, USA. 3University of Oklahoma Health Science Center, Oklahoma City, OK, USA


8

TITLE: UPSHAW SCHULMAN SYNDROME IS A RARE MASQUERADER OF ATYPICAL HEMOLYTIC SYNDROME & THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) IN PREGNANCY RELATED THROMBOTIC MICROANGIOPATHY (P-TMA).
Fnu Kaweeta, Sandeep K Rajan. UTHSC, Memphis, TN, USA


14

THE RATIO OF VON WILLEBRAND FACTOR:ANTIGEN / ADAMTS-13 IN CANCER PATIENTS WITH CHEMOTHERAPY AS DISCRIMINANT VARIABLE TO PREDICT EARLY DEEP VEIN THROMBOSIS
Ridho M. Naibaho1, 2, Budi Setiawan3, Eko A. Pangarsa3, Damai Santosa3, Suyono Suyono3, Mika Lumbantobing3, Catharina Suharti3. 1Fellow in Hematology and Medical Oncology, Semarang, Indonesia. 2Dept. of Medicine, Medical Faculty of Mulawarman University and Parikesit Hospital, Kutai Kartanegara, Indonesia. 3Division of Hematology and Medical Oncology, Dept. of Medicine, Medical Facultty of Diponegoro University and Dr. Kariadi Hospital, Semarang, Indonesia


15

HEMODYNAMIC AND VENTILATORY RESPONSES DURING EXERCISE IN PEDIATRIC PATIENTS WITH PULMONARY EMBOLISM
Mackenzie Parker, Tony Babb, Michael D Nelson, Ayesha Zia. University of Texas Southwestern Medical Center, Dallas, TX, USA


21

VENOUS THROMBOEMBOLISM HOSPITALIZATION AND RELATED DEATH: ANALYSIS OF THE NATIONWIDE READMISSIONS DATABASE
Guillermo Tafur1, Alfonso Tafur2, Kambiez Zorriasateyn2, Cheong Lee2. 1Loyola University Medical Center, Maywood, IL, USA. 2Northshore University health Systems, Skokie, IL, USA


25

PEDIATRIC RENAL RHABDOID CELLS CONSTITUTIVELY EXPRESS HEMOSTATIC SYSTEM FACTORS AND THE PROTEIN EXPRESSION IS AFFECTED BY CHEMOTHERAPY
Hanjie Zhu, Ghada Aborkhees, Kevin Dietrich , Lesley Mitchell. Department of Pediatrics, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada